Isofol Medical

What Isofol Medical does

Isofol Medical AB (publ) is a Swedish clinical-stage biotechnology company founded in 2008 and headquartered at Biotech Center in Gothenburg. The company is developing arfolitixorin, a patented next-generation folate-based drug candidate designed to enhance the efficacy of standard 5-FU-based chemotherapy in treating metastatic colorectal cancer and other solid tumors. Arfolitixorin is positioned by the company as the first and only directly-acting folate that does not require metabolic conversion in the body, allowing higher tumor tissue concentrations than existing folate therapies. Isofol holds a global license from Merck & Cie/Merck Life Science KGaA for the [6R]-MTHF compound, with new product patent protection secured via the European Patent Office until 2043 and FDA Fast Track Designation granted in 2021.

The company operates with a lean organizational structure of 11–50 employees, supplemented by a contracted network of consultants covering research, CMC, QA, patents, and clinical drug development. Manufacturing is outsourced to Recipharm in Wasserburg, Germany, and clinical operations are executed through Link Medical (CRO) and Charité – Universitätsmedizin Berlin, where a new Phase Ib/II study with an optimized dosing regimen is ongoing following the 2022 failure of the Phase III AGENT study to meet its primary endpoint. The company is publicly listed on Nasdaq Stockholm under the ticker ISOFOL since 2021.

Isofol's business model is asset-light and licensing-driven rather than commercial. The company has no commercial revenue (0 TSEK for full-year 2025) and monetizes future commercialization through regional partners: Solasia Pharma K.K. for Japan (up to $100M in upfront and milestone payments plus tiered double-digit royalties) and Knight Therapeutics for Canada. The US market — representing the bulk of the addressable opportunity (>10 BSEK annual sales potential based on Back Bay Life Science Advisors analysis) — remains unpartnered. In March 2026 Isofol expanded its global exclusive license to include autism spectrum disorder / cerebral folate deficiency, signaling an intent to broaden arfolitixorin's therapeutic footprint beyond oncology.

Name

Isofol Medical

Legal name

Isofol Medical AB (publ)

Website

https://isofolmedical.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Isofol Medical is a Swedish clinical-stage biotechnology company developing arfolitixorin, a directly-acting folate drug candidate designed to enhance 5-FU-based chemotherapy in metastatic colorectal cancer and other solid tumors, with a licensing-driven business model and listing on Nasdaq Stockholm.

Ownership category

akta.pro rank

Headquarters

HQ city

Gothenburg

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Licensing and Royalties: Pre-commercial stage company. Revenue expected from licensing agreements with regional partners for development and commercialization rights. Current agreements include Solasia Pharma K.K. (Japan) with potential $100 million in upfront and milestone payments plus tiered double-digit royalties on future net sales, and Knight Therapeutics (Canada).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Isofol Medical is a publicly listed clinical-stage biotechnology company developing arfolitixorin, a patented next-generation folate-based drug candidate (6R-MTHF) designed to enhance the efficacy of standard 5-FU-based chemotherapy in first-line treatment of metastatic colorectal cancer and other solid tumors. The company operates without commercial products, generating pre-revenue licensing and milestone-based income from regional partners.

Product overview

Isofol Medical is a publicly listed biotechnology company developing a single drug candidate, arfolitixorin. Arfolitixorin is a next-generation folate designed to enhance the efficacy of standard first-line cancer treatments (5-FU-based chemotherapy) for solid tumors, particularly metastatic colorectal cancer. The company is currently conducting a Phase Ib/II clinical study with an optimized dosing regimen at Charité – Universitätsmedizin Berlin in Germany, with plans to expand to Japan through partner Solasia Pharma K.K.

Differentiator

Problem solved

Functional benefit

Products and services

• Arfolitixorin Arfolitixorin is the first and only directly-acting folate form (6R-MTHF) that does not require metabolic conversion in the body. It is designed to enhance the efficacy of 5-FU-based chemotherapy in first-line treatment of metastatic colorectal cancer and other solid tumors, currently being evaluated in a Phase Ib/II study at Charité – Universitätsmedizin Berlin.

Quantifiable outcome

• All patients (n=6 evaluated) showed tumor shrinkage with up to 50% reduction in total tumor burden; half became candidates for tumor surgery (typically not feasible in this RAS-mutated population).
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core.

• Charité – Universitätsmedizin BerlincoreStrategic or Co-development Partner · 1 January 2024Collaboration agreement for conducting the clinical phase Ib/II study of arfolitixorin in Germany. Prof. Dr. med. Sebastian Stintzing serves as coordinating principal investigator. The study is conducted at the Department of Hematology, Oncology, and Cancer Immunology under his leadership. Collaboration focuses on colorectal cancer and other solid tumors.
• Merck Life Science KGaA / Merck & CiecoreStrategic or Co-development Partner · 1 January 2020Strategic research and development partnership with global license agreement. Merck provides expertise in substance development including synthesis of stable API (active pharmaceutical ingredient) of [6R]-MTHF and formulation of stable drug product. Isofol has specialized knowledge in development and use of arfolitixorin for cancer treatment. Ongoing collaboration on intellectual property rights, patents, and further product development.
• Solasia Pharma K.K.coreOEM/ Whitelabel/ Licensing Partner · 1 January 2020Regional license agreement for Japan, the world's second largest pharmaceutical market. Deal value of $100 million in upfront payments and future milestone payments tied to clinical development, regulatory process, and sales. Isofol entitled to tiered double-digit royalties on future net sales. Solasia committed to financing Phase II study in Japan starting 2026.
• Knight Therapeutics Inc. (formerly Paladin Labs Inc.)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2020License agreement covering commercialization on the Canadian market with royalty revenues on future sales.
• RecipharmcoreOthers · 1 January 2015Manufacturing partner since 2015 at Recipharm in Wasserburg, Germany. Large-scale production process in place. Isofol maintains close dialogue with Recipharm to ensure manufacturing and delivery for clinical studies.
• Link MedicalcoreImplementation/ SI/ Consulting PartnerClinical Research Organization (CRO) assisting with practical implementation of clinical studies including statistical calculations and analyses, database management for study data, preclinical studies, and distribution of study medication. Link Medical is Isofol's primary CRO driving the clinical study on behalf of and in collaboration with Isofol.

Scale indicators6 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Aprea Therapeutics: Clinical-stage oncology drug developer with similar single-asset profile and Swedish/Scandinavian roots. Isofol's CMO Roger Tell was previously VP Clinical Development at Aprea, indicating direct operational overlap in cancer drug development strategy and stage.
• Solasia Pharma K.K. Japanese specialty pharmaceutical company that is Isofol's regional licensee for Japan. Comparable as a clinical/commercial-stage oncology drug developer with similar partnership-driven business model targeting the Asia-Pacific market.
• Vivesto: Swedish specialty oncology pharma company listed on Nasdaq Stockholm. Comparable as a small-cap Nordic oncology developer focused on solid tumor therapeutics; Isofol's CMO Roger Tell serves on Vivesto's board, indicating overlapping management networks and similar investor base.
• Cantargia: Swedish clinical-stage biotech developing antibody-based cancer therapies. Comparable as a small-cap Nordic oncology developer with a Nasdaq Stockholm listing, focused on solid tumors with partnership-driven geographic expansion.
• BioInvent: Swedish clinical-stage biotech listed on Nasdaq Stockholm developing immuno-oncology antibodies. Comparable as a similarly-sized Nordic oncology biotech with multiple clinical assets and partnership-driven commercialization model.

Emerging players

• Mendus: Swedish clinical-stage biotech (formerly Immunicum) developing cellular immunotherapies for cancer. Comparable as a small-cap Nordic oncology developer with similar Nasdaq Stockholm listing and licensing/regional partnership approach to commercialization.

Broad incumbents

• Eli Lilly: Global pharmaceutical incumbent that manufactures leucovorin (folinic acid), the closest mechanistic alternative to arfolitixorin. Comparable as a broad oncology and supportive-care pharma player whose established folate franchise defines the competitive landscape Isofol would enter.
• Pfizer: Global pharmaceutical incumbent that markets Adrucil (fluorouracil/5-FU), the backbone chemotherapy that arfolitixorin enhances. Comparable as a broad oncology incumbent that defines the standard-of-care regimen Isofol's drug is designed to combine with.
• Merck KGaA: Parent of Merck & Cie, Isofol's strategic R&D partner and original licensor of arfolitixorin technology. Comparable as a global life sciences incumbent with deep expertise in folate chemistry and pharmaceutical manufacturing that underpins the asset.

Regional players

• Knight Therapeutics: Canadian specialty pharmaceutical company and Isofol's regional licensee for Canada. Comparable as a smaller regional pharma with a licensing-and-royalty business model focused on commercializing innovative therapies in a single geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/isofolmedical
• LinkedInlinkedin.com/company/isofol-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Isofol Medical